The government negotiated with the manufacturers to reduce the price the government will pay to $250 for a months supply and in return the companies will have access to the larger patient population
Format Research-use compound Latest result CoA uploaded Certificate CoA uploaded
6.4 D&D Pharmatech + Metsera + Pfizer D&D Pharmatech, a Korean biotechnology company, licensed its DD-03 and DD-15 preclinical triple-agonist assets to Metsera, a U.S
However, this remains unproven for alcohol-specific outcomes, and users choosing Retatrutide are essentially participating in an informal experiment without the protections of formal clinical trials
Restore Peptides emphasizes the importance of U.S
I've heard you say, you know, I spent 25 years treating this condition without a decent pharmaceutical option and five years with one